Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the effect of boceprevir (steady state) on the
pharmacokinetics of a single dose of raltegravir. The effect on the boceprevir
pharmacokinetics of a single dose raltegravir will also be evaluated (compared to historical
controls). Furthermore, the safety profile of the combination is studied.
Phase:
Phase 1
Details
Lead Sponsor:
Radboud University
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
HIV Integrase Inhibitors HIV Protease Inhibitors Integrase Inhibitors Protease Inhibitors Raltegravir Potassium